Pharmacological approaches to the management of schizophrenia: 10 years on

David Jonathan Castle, Nicholas Alexander Keks, Richard Newton, Isaac Schweitzer, David Leon Copolov, Nick Paoletti, Graham D Burrows, Tiller W G John

Research output: Contribution to journalArticleResearchpeer-review

6 Citations (Scopus)

Abstract

OBJECTIVE: To review the contemporary landscape regarding pharmacological treatments for schizophrenia. METHOD: Selective literature review. RESULTS: Newer antipsychotic agents include aripiprazole, asenapine, paliperidone, sertindole and ziprasidone. Each has some particular benefits and some shortcomings. Overall treatment efficacy (for positive symptoms at least) has not advanced substantially but some newer agents might have a better profile than older typical agents for negative and cognitive symptoms. Metabolic side effects and hyperprolactinaemia remain a problem with some of the newer agents and appropriate monitoring is required. CONCLUSIONS: Whilst newer antipsychotics have been welcome additions to our pharmacological armamentarium, mostly in terms of tolerability, we have still not seen a quantum leap agent brought to market. Mechanisms of action apart from post-synaptic dopamine blockade appear worthy of further investigation in this regard.
Original languageEnglish
Pages (from-to)329 - 334
Number of pages6
JournalAustralasian Psychiatry
Volume21
Issue number4
DOIs
Publication statusPublished - 2013

Cite this

Castle, David Jonathan ; Keks, Nicholas Alexander ; Newton, Richard ; Schweitzer, Isaac ; Copolov, David Leon ; Paoletti, Nick ; Burrows, Graham D ; John, Tiller W G. / Pharmacological approaches to the management of schizophrenia: 10 years on. In: Australasian Psychiatry. 2013 ; Vol. 21, No. 4. pp. 329 - 334.
@article{07d33ebf3f8c40f6ac156ad8df7ad4bd,
title = "Pharmacological approaches to the management of schizophrenia: 10 years on",
abstract = "OBJECTIVE: To review the contemporary landscape regarding pharmacological treatments for schizophrenia. METHOD: Selective literature review. RESULTS: Newer antipsychotic agents include aripiprazole, asenapine, paliperidone, sertindole and ziprasidone. Each has some particular benefits and some shortcomings. Overall treatment efficacy (for positive symptoms at least) has not advanced substantially but some newer agents might have a better profile than older typical agents for negative and cognitive symptoms. Metabolic side effects and hyperprolactinaemia remain a problem with some of the newer agents and appropriate monitoring is required. CONCLUSIONS: Whilst newer antipsychotics have been welcome additions to our pharmacological armamentarium, mostly in terms of tolerability, we have still not seen a quantum leap agent brought to market. Mechanisms of action apart from post-synaptic dopamine blockade appear worthy of further investigation in this regard.",
author = "Castle, {David Jonathan} and Keks, {Nicholas Alexander} and Richard Newton and Isaac Schweitzer and Copolov, {David Leon} and Nick Paoletti and Burrows, {Graham D} and John, {Tiller W G}",
year = "2013",
doi = "10.1177/1039856213486211",
language = "English",
volume = "21",
pages = "329 -- 334",
journal = "Australasian Psychiatry",
issn = "1039-8562",
publisher = "SAGE Publications Ltd",
number = "4",

}

Pharmacological approaches to the management of schizophrenia: 10 years on. / Castle, David Jonathan; Keks, Nicholas Alexander; Newton, Richard; Schweitzer, Isaac; Copolov, David Leon; Paoletti, Nick; Burrows, Graham D; John, Tiller W G.

In: Australasian Psychiatry, Vol. 21, No. 4, 2013, p. 329 - 334.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Pharmacological approaches to the management of schizophrenia: 10 years on

AU - Castle, David Jonathan

AU - Keks, Nicholas Alexander

AU - Newton, Richard

AU - Schweitzer, Isaac

AU - Copolov, David Leon

AU - Paoletti, Nick

AU - Burrows, Graham D

AU - John, Tiller W G

PY - 2013

Y1 - 2013

N2 - OBJECTIVE: To review the contemporary landscape regarding pharmacological treatments for schizophrenia. METHOD: Selective literature review. RESULTS: Newer antipsychotic agents include aripiprazole, asenapine, paliperidone, sertindole and ziprasidone. Each has some particular benefits and some shortcomings. Overall treatment efficacy (for positive symptoms at least) has not advanced substantially but some newer agents might have a better profile than older typical agents for negative and cognitive symptoms. Metabolic side effects and hyperprolactinaemia remain a problem with some of the newer agents and appropriate monitoring is required. CONCLUSIONS: Whilst newer antipsychotics have been welcome additions to our pharmacological armamentarium, mostly in terms of tolerability, we have still not seen a quantum leap agent brought to market. Mechanisms of action apart from post-synaptic dopamine blockade appear worthy of further investigation in this regard.

AB - OBJECTIVE: To review the contemporary landscape regarding pharmacological treatments for schizophrenia. METHOD: Selective literature review. RESULTS: Newer antipsychotic agents include aripiprazole, asenapine, paliperidone, sertindole and ziprasidone. Each has some particular benefits and some shortcomings. Overall treatment efficacy (for positive symptoms at least) has not advanced substantially but some newer agents might have a better profile than older typical agents for negative and cognitive symptoms. Metabolic side effects and hyperprolactinaemia remain a problem with some of the newer agents and appropriate monitoring is required. CONCLUSIONS: Whilst newer antipsychotics have been welcome additions to our pharmacological armamentarium, mostly in terms of tolerability, we have still not seen a quantum leap agent brought to market. Mechanisms of action apart from post-synaptic dopamine blockade appear worthy of further investigation in this regard.

UR - http://apy.sagepub.com/content/21/4/329.full.pdf

U2 - 10.1177/1039856213486211

DO - 10.1177/1039856213486211

M3 - Article

VL - 21

SP - 329

EP - 334

JO - Australasian Psychiatry

JF - Australasian Psychiatry

SN - 1039-8562

IS - 4

ER -